Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 4(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01657669Phase 4Unknown

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Role: collaborator

NCT02630277Phase 2Unknown

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN

Role: lead

NCT01827722Phase 4Unknown

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

Role: lead

NCT01486238Phase 4Completed

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Role: lead

NCT01486771Phase 4Unknown

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Role: lead

All 5 trials loaded